Palisade Bio (PALI) Cash & Equivalents (2010 - 2026)

Palisade Bio (PALI) has reported Cash & Equivalents for 17 consecutive years, with $132.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 1734.41% year-over-year to $132.6 million; the TTM figure through Mar 2026 stood at $132.6 million (up 1734.41% YoY), while the FY2025 annual figure was $132.4 million, up 1256.13% from the prior year.
• Cash & Equivalents steadied at $132.6 million in Q1 2026 per PALI's latest filing, from $132.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $132.6 million in Q1 2026 and bottomed at $5.0 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $24.6 million across 5 years, with a median of $11.4 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 60.64% — and 2026, when it surged 1734.41%.
• Palisade Bio's Cash & Equivalents stood at $12.4 million in 2022, then advanced by 0.4% to $12.4 million in 2023, then dropped by 21.47% to $9.8 million in 2024, then surged by 1256.13% to $132.4 million in 2025, then climbed by 0.17% to $132.6 million in 2026.
• Business Quant data shows PALI's Cash & Equivalents at $132.6 million in Q1 2026, $132.4 million in Q4 2025, and $5.2 million in Q3 2025.